JP2017528431A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528431A5
JP2017528431A5 JP2017502821A JP2017502821A JP2017528431A5 JP 2017528431 A5 JP2017528431 A5 JP 2017528431A5 JP 2017502821 A JP2017502821 A JP 2017502821A JP 2017502821 A JP2017502821 A JP 2017502821A JP 2017528431 A5 JP2017528431 A5 JP 2017528431A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
inhibitor
composition
active
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017502821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528431A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/040879 external-priority patent/WO2016011335A1/en
Publication of JP2017528431A publication Critical patent/JP2017528431A/ja
Publication of JP2017528431A5 publication Critical patent/JP2017528431A5/ja
Pending legal-status Critical Current

Links

JP2017502821A 2014-07-17 2015-07-17 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム Pending JP2017528431A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462025714P 2014-07-17 2014-07-17
US62/025,714 2014-07-17
PCT/US2015/040879 WO2016011335A1 (en) 2014-07-17 2015-07-17 Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems

Publications (2)

Publication Number Publication Date
JP2017528431A JP2017528431A (ja) 2017-09-28
JP2017528431A5 true JP2017528431A5 (enExample) 2018-08-16

Family

ID=55079079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502821A Pending JP2017528431A (ja) 2014-07-17 2015-07-17 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム

Country Status (9)

Country Link
US (1) US20170173060A1 (enExample)
EP (1) EP3169331A4 (enExample)
JP (1) JP2017528431A (enExample)
KR (1) KR20170026635A (enExample)
CN (1) CN106687119A (enExample)
AU (1) AU2015289511A1 (enExample)
CA (1) CA2955425A1 (enExample)
IL (1) IL250170A0 (enExample)
WO (1) WO2016011335A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999721B2 (en) 2009-10-23 2015-04-07 Therabrake, Inc. Method and system to provide personalized pharmaceutical compositions and dosages
US20180099001A1 (en) 2011-04-29 2018-04-12 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
EP3294308A4 (en) 2015-05-14 2019-03-06 University of Puerto Rico PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN
LT3393496T (lt) 2015-12-23 2023-12-11 The Johns Hopkins University Ilgo veikimo glp-1r agonistas, kaip neurologinių ir neurodegeneracinių būklių terapija
US11564667B2 (en) 2015-12-28 2023-01-31 New York University Device and method of restoring microbiota of newborns
US10398389B1 (en) 2016-04-11 2019-09-03 Pricewaterhousecoopers Llp System and method for physiological health simulation
WO2017203367A2 (en) * 2016-05-22 2017-11-30 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
JP2020507626A (ja) 2017-02-10 2020-03-12 イノベイト バイオファーマシューティカルズ インコーポレイテッド 腸上皮の透過性と関連する疾患を治療する組成物及び方法
WO2018204918A1 (en) * 2017-05-05 2018-11-08 Ardelyx, Inc. Treatment of hepatic disorders
CN111094537A (zh) * 2017-09-08 2020-05-01 自然免疫制御技术研究组合 阿尔茨海默症诊断装置及方法
KR102282490B1 (ko) 2018-01-12 2021-07-28 주식회사 엠디헬스케어 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도
CN120241688A (zh) * 2018-01-12 2025-07-04 麦提麦迪制药有限公司 乳酸钙在制备用于治疗疾病的药物组合物、食物或营养组合物中的用途
KR20200128407A (ko) * 2018-03-02 2020-11-12 노바리크 게엠베하 네비볼롤을 포함하는 약제학적 조성물
CN112074197A (zh) * 2018-03-07 2020-12-11 安纳生物科技有限公司 用于ii型糖尿病及用于提供随着时间的持续的能量释放的组合物
US10803981B2 (en) 2018-10-15 2020-10-13 James Glenn Norman Applied artificial intelligence technology for hormone therapy treatment
WO2020081369A1 (en) * 2018-10-15 2020-04-23 James Glenn Norman Applied artificial intelligence technology for hormone therapy treatment
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
KR20220079652A (ko) * 2019-10-11 2022-06-13 에프. 호프만-라 로슈 아게 약물 투약 결정 디바이스 및 방법
US20230241064A1 (en) * 2020-01-08 2023-08-03 Resverlogix Corp. Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor
CN117056370A (zh) * 2020-03-19 2023-11-14 上海太美星云数字科技有限公司 医学数据处理方法、装置、设备和存储介质
US20240266069A1 (en) * 2021-05-19 2024-08-08 Charité – Universitätsmedizin Berlin Computer assisted method for the evaluation of cardiac metabolism
CN113362925B (zh) * 2021-06-29 2022-04-08 山东第一医科大学附属省立医院(山东省立医院) 一种自动良肢位控制方法及设备
CN114705871A (zh) * 2022-04-12 2022-07-05 复旦大学附属中山医院 8异前列腺素F2α在重度哮喘诊断中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
JP2007517766A (ja) * 2003-09-24 2007-07-05 コンビナトアールエックス インコーポレーティッド 薬物の組み合わせを投与するための治療法
EP1919285A2 (en) * 2005-07-28 2008-05-14 Reliant Pharmaceuticals, Inc. Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
JP5513113B2 (ja) * 2006-08-31 2014-06-04 アプタリス ファーマテック,インコーポレイテッド 弱塩基性薬剤の固溶体を含む薬剤送達システム
US8999721B2 (en) * 2009-10-23 2015-04-07 Therabrake, Inc. Method and system to provide personalized pharmaceutical compositions and dosages
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
KR20140147657A (ko) * 2011-03-02 2014-12-30 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
CA2897448A1 (en) * 2013-01-08 2014-07-17 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems

Similar Documents

Publication Publication Date Title
JP2017528431A5 (enExample)
JP2015503593A5 (enExample)
EP3581173B1 (en) Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
JP5204846B2 (ja) エタノールの影響に対して耐性を有する非オピオイド薬のpH依存性制御放出医薬組成物
JP5619130B2 (ja) 中性ビニルポリマーおよび賦形剤を含むコーティングを使用するエタノールの影響に対する耐性を有する制御放出性医薬組成物
HRP20210686T1 (hr) Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom
JP2015522029A5 (enExample)
JP5453434B2 (ja) エタノールの影響に対する耐性を有するオピオイドではないpH依存の制御放出の医薬組成物
JP2019048843A5 (enExample)
JP2017528516A5 (enExample)
JP2015503590A5 (enExample)
US20110311631A1 (en) Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
RU2018120726A (ru) Комбинации с гемкабеном для лечения заболеваний сердечно-сосудистой системы
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
ES2623176T3 (es) Composición farmacéutica de memantina
JP2007119479A5 (enExample)
JPWO2014050692A1 (ja) 糖尿病新規発症低減用組成物
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
Bader et al. Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro
KR20090114325A (ko) 약제학적 제제
RU2014127884A (ru) Способы лечения сердечно-сосудистого нарушения
JP2005538121A5 (ja) 多重遅延放出抗ウイルス物質産物、その使用法と製剤
ES2299072T3 (es) Procedimiento para la preparacion de formas medicamentosas con perfil de liberacion de principio activo estable.
MXPA04006780A (es) Formulaciones farmaceuticas de pravastatina y metodos para usarlas.
EP2197439A2 (en) Pharmaceutical composition for treating hepatitis c virus infection comprising hmg-coa reductase inhibitor and bile acid